Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors

publication date: Mar 7, 2018

Oxford Vacmedix, a UK-Changzhou biopharma, closed a $12.5 million Series A funding from South Korean and China investors to develop therapeutic cancer vaccines. OVM's two lead vaccines target cervical cancer and solid tumors, respectively, by stimulating CD4 and CD8 responses. The company expects the money will be enough to complete pre-clinical development of the vaccines and begin Phase I trials. Investors in the funding were Cancer ROP, a South Korea diagnostics company, and existing shareholders in China, who also supported the company's Changzhou facility. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital